Among all the TP53 and enriched pathway genes, SPAG5 was identified as the most influential gene for the TCGA and BEAT AML patient groups on the basis of the average strength of influence across the two datasets (see Fig. 7), indicating that SPAG5 is a key driver and potential therapeutic target for AML. This evidence concerns the gene TP53 and acute myeloid leukemia.